It's there a correlation between amyloidosis and long covid

There is no direct established clinical correlation between amyloidosis and long COVID in current UK clinical guidelines, as amyloidosis is not listed among recognized post-COVID conditions or complications. Long COVID is defined as a multi-system syndrome including fatigue, cognitive impairment, respiratory issues, and auto-immune phenomena persisting beyond 4 weeks after acute infection, without alternative explanation NICE CKS,NICE CKS. Amyloidosis—particularly cardiac forms such as AL (light-chain) and ATTR (transthyretin) amyloidosis—is a distinct pathological condition involving abnormal amyloid protein deposition causing organ dysfunction, primarily discussed in cardiology literature Alkhatib et al. 2025.

However, emerging scientific literature on long COVID suggests persistent inflammatory and immune dysregulation following SARS-CoV-2 infection, with chronic elevation of inflammatory markers including serum amyloid A protein (SAA), which is known to be involved in secondary amyloidosis formation. Ahmed et al. 2025 demonstrated that in COVID-19 patients, SAA levels were significantly elevated acutely and normalized over a month, whereas other markers like IL-6, CRP, and heparin-binding protein (HBP) persisted elevated longer, indicating ongoing inflammation post-infection Ahmed et al. 2025. Persistent elevation of SAA is linked to amyloidosis pathogenesis in other conditions, highlighting a theoretical mechanistic link between sustained inflammation in long COVID and amyloid deposition processes.

Additionally, long COVID is associated with neurological and multisystem immune dysregulation, and recent studies indicate SARS-CoV-2 infection might accelerate amyloidogenic pathways in the brain, neuroinflammation, and neurodegeneration resembling Alzheimer’s disease mechanisms, although these processes differ from systemic amyloidosis syndromes clinically managed in cardiology and haematology Stigliano et al. 2026.

In summary, while no direct clinical evidence currently confirms that long COVID causes or is correlated with amyloidosis as a systemic disease, there is biological plausibility linking prolonged inflammatory responses (e.g., elevated SAA) in COVID-19 survivors to amyloid-related pathology. Further longitudinal observational and mechanistic studies are needed to clarify whether long COVID inflammation predisposes to amyloidosis, particularly in susceptible populations.